The first tranche in $CYBN (+5,39%) was made as a highly speculative investment, primarily on the basis of the following assumptions:
Megatrend psychedelics:
They are positioning themselves in the emerging market of psychedelic medicine, which has the potential to revolutionize the treatment of mental illnesses (such as Major Depressive Disorder).
High multiplier potential ("tenfold"):
As Cybin has not yet generated any sales (pre-revenue), the share value is almost entirely dependent on clinical success. A positive outcome of the ongoing phase 3 trials for the lead product CYB003 could trigger a massive revaluation of the company.
Scientific lead:
Cybin is focusing on innovative, modified molecules (Deuterated Psychedelics) that are expected to provide improved efficacy and shorter duration of therapy, which could provide a competitive advantage over pure psilocybin approaches.
To summarize:
The entry is a conscious risk decision on a scientific breakthrough that promises significant profits if successful.
